Practice practice practice!
What are your findings?
How would this change management?
Try not to cheat!
Some articles and other resources:
The Seminars in Neuropsychiatry has moved to: www.eratne.net/seminars
Click here for the full list of publications on PubMed (currently only first author displays below, unfortunately)
- Investigation of structural brain correlates of neurological soft signs in individuals at ultra-high risk for psychosisIncreased severity of neurological soft signs (NSS) in schizophrenia have been associated with abnormal brain morphology in cerebello-thalamo-cortical structures, but it is unclear whether similar structures underlie NSS prior to the onset of psychosis. The present study investigated the relationship between severity of NSS and grey matter volume (GMV) in individuals at ultra-high risk for psychosis (UHR) stratified for later conversion to psychosis. Structural T1-weighted MRI scans were…
- CONCLUSION: This is the largest Australian study to date investigating survival and risk factors to mortality in dementia. We report important clinical information to patients with dementia and their families about prognosis which will assist with future planning. Our findings suggest that for both older-onset dementia and younger-onset dementia, 'new onset' psychiatric symptoms precede the cognitive symptoms of a neurodegenerative process. This, and sex differences in survival depending on the…
- A call to action for the improved identification, diagnosis, treatment and care of people with young onset dementiaNo abstract
- CONCLUSION: Our final outcome was the Secondary Schizophrenia Suspicion Index, the first paper-based and reliable algorithm to discriminate secondary schizophrenia spectrum disorders from schizophrenia spectrum disorders with the potential to help improve the detection of secondary schizophrenia spectrum disorder cases in clinical practice.
- Deep brain stimulation for treatment-refractory obsessive-compulsive disorder should be an accepted therapy in AustraliaDeep brain stimulation has shown promise for the treatment of severe, treatment-refractory obsessive-compulsive disorder. With the recent publication of the first Australian, randomised, sham-controlled trial of deep brain stimulation for obsessive-compulsive disorder, there are now four placebo-controlled trials demonstrating the efficacy of this therapy. Together with recent data identifying a biological substrate of effective stimulation that can predict response and that has been…
- Brain hypometabolism in rare genetic neurodegenerative disease: Niemann-Pick disease type C, spinocerebellar ataxia and Huntington disease assessed by FDG PETBrain metabolic imaging using ^(18)F-fluorodeoxyglucose (FDG) Positron Emission Tomography (PET) with contemporaneous low-dose CT may be used to assess neurodegenerative diseases. In contrast to oncology whole-body FDG PET, qualitative assessment alone in brain FDG PET is subjective and vulnerable to visual interference due to high physiologic background activity. Therefore, mild changes in brain metabolism may be visually undetectable by qualitative interpretation alone, resulting in diagnostic…
- Differential involvement of hippocampal subfields in Niemann-Pick type C disease: a case-control studyHippocampal brain regions are strongly implicated in Niemann Pick type C disease (NPC), but little is known regarding distinct subregions of the hippocampal complex and whether these are equally or differentially affected. To address this gap, we compared volumes of five hippocampal subfields between NPC and healthy individuals using MRI. To this end, 9 adult-onset NPC cases and 9 age- and gender-matched controls underwent a 3 T T1-weighted MRI scan. Gray matter volumes of the cornu ammonis…
- CONCLUSIONS: This is the largest cohort of NPC patients investigated for ocular-motor function. Vertical supranuclear saccade palsy is the hallmark of NPC. Vertical upward and downward saccades are equally impaired. Horizontal saccadic peak velocity and latency, vertical saccadic duration and amplitude, and horizontal position smooth pursuit can be used as surrogate parameters for clinical trials. Compensating strategies can contribute to establishing a diagnosis.
- Psychiatric and cognitive characteristics of older adults admitted to a Video-EEG monitoring (VEM) unitCONCLUSION: Psychiatric comorbidities are common among older adults admitted for VEM. The psychological impact of epilepsy and risk factors for PNES seen in younger patients are also applicable in the older group. The older group demonstrated more cognitive impairments than the younger group, although these were usually unrecognized by individuals. Older adults admitted to VEM will benefit from psychiatric and neuropsychological input to ensure a comprehensive care approach to evaluation and…
- Pathophysiology and management of neuropsychiatric symptoms in succinic semialdehyde dehydrogenase deficiencyNo abstract
RMH-Alfred-Concord and RANZCP VIC Section of Neuropsychiatry
Seminars in Neuropsychiatry
Dates set for 2021!
Neuropsychiatry at the Royal Melbourne, Alfred and Concord Hospitals, and the RANZCP Victorian Section of Neuropsychiatry, are pleased to have several seminars planned for 2021. Please spread the word to colleagues far and wide with this link: www.eratne.net/seminars
To receive details on how to attend sessions, for any queries, feedback, to suggest potential future topics, and to be put on the email list, please contact us.
Save the dates for these upcoming seminars, 8-9am (AEST/Melbourne time) on the following Tuesdays:
6 April: A/Professor Andrew Evans, neurologist at Neuropsychiatry RMH, and head of movement disorders RMH: The Neurological Examination
11 May: Dr Nicola Warren – Autoimmune encephalitis: how should we screen, diagnose and treat?
15 June: Dr Samantha Loi – Younger Onset Dementia
20 July: Topic and speaker TBC
31 August: Professor Harry McConnell – Neuropsychiatry of Epilepsy “Seizures and Snowflakes”
5 October: A/Professor Amy Brodtmann – topic TBC
7 December: A/Professor Ravi Bhat – Delirium
Dr Dhamidhu Eratne
Dr Toby Winton-Brown
Dr Andrew Gleason
Professor Dennis Velakoulis
on behalf of the RANZCP Section of Neuropsychiatry Victorian Subcommittee
We hope you’ve enjoyed our RMH-Alfred Neuropsychiatry Education Series this year, and we look forward to seeing you next year.
– Dhamidhu Eratne, Toby Winton-Brown, Dennis Velakoulis, and many others, on behalf of the Section of Neuropsychiatry and Royal Melbourne Hospital and the Alfred
Thank you to all our excellent speakers for their time, and special mention and thanks to Kate Egan, Nicholas Burgess, and Lily Ward for keeping the lecture series afloat.
Now it’s feedback time!
Please go to this website to give us some (anonymous) feedback:
This research and clinically focussed event promises to offer a broad overview of current issues in genetics in neurodegenerative disorders, and should be of interest to a wide range of clinicians, researchers and scientists in the neurosciences.
Ticketing has been reopened!
Register now via this Eventbrite link: https://bit.ly/2Y3CJjz
Please contact Dr Dhamidhu Eratne (firstname.lastname@example.org) if you have any queries.
Programme and Speakers:
Monday 12 August, 1400-1730
Venue TBC at MCRI/RCH – trying to get larger venue
1400-1500 Glenda Halliday (confirmed) – opening plenary – “Overview of neurodegenerative genetics and why NGS is needed”
1500-1520 (15min + 5min for questions) Dhamidhu Eratne (confirmed) – “WES, What is it Good for (in Neurodegenerative Disorders)? Updates from the Melbourne Genomics Complex Neurology Flagship”
1520-1540 (15min + 5min for questions) Martin Delatycki and David Szmulewicz (confirmed) – “Genetic ataxia- what is the latest about aetiology and treatment?”
1600-1620 (15min + 5min for questions) Aamira Huq (confirmed) – “The Paradox of the Young Demented and the Old Resilient – Can Genetics Explain?”
1620-1640 (15min + 5min for questions) Melanie Bahlo (confirmed) – “Repeat Expansion Detection from NGS Data for Neurodegenerative Disorders”
1640-1700 (15min + 5min for questions) Sam Berkovic (confirmed) – “Genetics in Epilepsy”
1700-1730 (20-25 + 5-10min for questions) Steve Petrou (confirmed) – “The Promise of Antisense Oligonucleotide Therapy in Neurogenetic Disorders”